BioPharma Resources

Drug Trial Radar · NCT07493304

Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

A 2-Part, Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against Factor XI, for the Treatment and Secondary Prevention of Venous Thromboembolism in Participants With Solid and Hematologic Cancers (ROXI-CAT-II)

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,600

Planned (sponsor's estimate)

Start

Aug 26, 2026

Primary completion

Jul 18, 2031

Study completion Jul 18, 2031

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Mar 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called REGN7508 (called "study drug") and will consist of 2 parts: Part 1 and Part 2. The study is focused on participants with or without cancer who develop blood clots in certain veins (called Deep Vein Thrombosis \[DVT\]) that block blood flow (Part 1) or focused on participants with cancer who develop blood clots in certain veins (DVT) or the lungs (also called Pulmonary Embolism \[PE\]) (Part 2). The aim of the study is to see how safe and effective the study drug is at treating and preventing further blood clots in participants with or without cancer (Part 1) or in participants with cancer (Part 2) compared with another treatment (apixaban). The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Conditions

  • Venous Thromboembolism (VTE)

Interventions

  • REGN7508Drug

    Administered per the protocol

  • ApixabanDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Approximately 6 months
  2. Severity of TEAEsTime frame: Approximately 6 months
  3. Time-to-first event of centrally adjudicated recurrent VTE [DVT (symptomatic or asymptomatic [proximal] or Non-fatal PE (symptomatic or asymptomatic [in a segmental or larger pulmonary artery] )or VTE-related death)]Time frame: Up to approximately 3.5 years
  4. Time-to-first event of centrally adjudicated International Society of Thrombosis and Hemostasis (ISTH)-defined major bleeding or Clinically Relevant Non-Major (CRNM) bleedingTime frame: Up to approximately 3.5 years

Locations

14 sites in 5 countries. Site status is shown where the registry gives one.

  • Bioresearch Partner- Hialeah Hospital

    Hialeah, Florida · Withdrawn

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • El Paso Medical Research Institute (Medresearch Inc)

    El Paso, Texas · Withdrawn

  • Arensia Exploratory Medicine, Multiprofile Hospital for Active Treatment Sveta Sofia

    Sofia, Bulgaria · Recruiting

  • Tokai University Hospital

    Isehara-Shi, Kanagawa, Japan · Recruiting

  • Tokyo Medical University Hospital

    Shinjuku, Tokyo, Japan · Recruiting

  • Yamaguchi University Hospital

    Ube, Yamaguchi, Japan · Recruiting

  • Institute of Oncology Bucharest

    Bucharest, Bucharest, Romania · Recruiting

  • Arensia Exploratory Medicine, The Oncology Institute "Prof. Dr. Ion Chiricuta"

    Cluj-Napoca, Cluj, Romania · Recruiting

  • Inje University, Haeundae Paik Hospital

    Busan, South Korea · Recruiting

  • Yonsei University Health System, Severance Hospital

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Yonsei University Health System, Yongin Severance Hospital

    Yongin-si, Gyeonggi-do, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.